» Articles » PMID: 15657617

Cascade Testing in Familial Hypercholesterolaemia: How Should Family Members Be Contacted?

Overview
Journal Eur J Hum Genet
Specialty Genetics
Date 2005 Jan 20
PMID 15657617
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Cascade testing or screening provides an important mechanism for identifying people at risk of a genetic condition. For some autosomal dominant conditions, such as familial hpercholesterolaemia (FH), identifying relatives allows for significant health-affecting interventions to be administered, which can extend a person's life expectancy significantly. However, cascade screening is not without ethical implications. In this paper, we examine one ethically contentious aspect of cascade screening programmes, namely the alternative methods by which relatives of a proband can be contacted. Should the proband be invited to contact his or her family members, or should the screening programme contact family members directly? We argue that direct contact is an ethically justifiable method of contact tracing in cascade screening for FH. Not only has this method already been utilised without adverse effects, an examination of the ethical arguments against it shows these are unsubstantiated. We describe several criteria that, if met, will allow an appropriate balance to be struck between maximising the efficiency of family tracing and respecting the interests of probands and their relatives.

Citing Articles

Healthcare provider-mediated cascade testing of Lynch syndrome to at-risk family members: an interview study.

Ong S, Chua Z, Yuen J, Chiang J, Zewen Z, Ngeow J Fam Cancer. 2025; 24(1):25.

PMID: 40011264 DOI: 10.1007/s10689-025-00450-2.


Privacy Implications of Contacting the At-Risk Relatives of Patients with Medically Actionable Genetic Predisposition, with Patient Consent: A Hypothetical Australian Case Study.

Tiller J, Nowak K, Boughtwood T, Otlowski M BioTech (Basel). 2023; 12(2).

PMID: 37366793 PMC: 10296322. DOI: 10.3390/biotech12020045.


Direct notification by health professionals of relatives at-risk of genetic conditions (with patient consent): views of the Australian public.

Tiller J, Stott A, Finlay K, Boughtwood T, Madelli E, Horton A Eur J Hum Genet. 2023; 32(1):98-108.

PMID: 37280361 PMC: 10242214. DOI: 10.1038/s41431-023-01395-9.


Approach to the Patient With a Suboptimal Statin Response: Causes and Algorithm for Clinical Management.

Sun L, Wolska A, Amar M, Zubiran R, Remaley A J Clin Endocrinol Metab. 2023; 108(9):2424-2434.

PMID: 36929838 PMC: 10438872. DOI: 10.1210/clinem/dgad153.


An Examination of the Ethical and Legal Limits in Implementing "Traceback Testing" for Deceased Patients.

Martucci J, Prado Y, Rope A, Weinmann S, White L, Zepp J J Law Med Ethics. 2023; 50(4):818-832.

PMID: 36883408 PMC: 10009393. DOI: 10.1017/jme.2023.23.